Alk Fusion Gene Positive Non Small Cell Lung Cancer — Patent Landscape
2
Approved drugs
21
Active US patents
32/100
Avg vulnerability
—
Annual revenue covered
Originators in Alk Fusion Gene Positive Non Small Cell Lung Cancer
Cliff calendar — next 15 years
4
27
2
28
2
30
4
32
2
33
4
36
1
37
2
38
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Zykadia
ceritinib
|
Novartis | 13 | 34 | — | 2027-11-20 |
|
Lorbrena
lorlatinib
|
Pfizer | 8 | 30 | — | 2033-03-05 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8377921 | Zykadia | method of use | 80 | 2027-11-20 |
| 8377921 | Zykadia | method of use | 75 | 2027-11-20 |
| 12357630 | Zykadia | method of use | 75 | 2037-12-13 |
| 8703787 | Zykadia | method of use | 73 | 2032-02-02 |
| 8703787 | Zykadia | method of use | 68 | 2032-02-02 |
| 10420749 | Lorbrena | method of use | 62 | 2036-07-27 |
| 10420749 | Lorbrena | method of use | 62 | 2036-07-27 |
| 11020376 | Lorbrena | formulation | 42 | 2036-07-27 |
| 11020376 | Lorbrena | formulation | 42 | 2036-07-27 |
| 7964592 | Zykadia | composition of matter | 22 | 2028-04-29 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8680111 | Lorbrena | composition of matter | 4 | 2033-03-05 |
| 8680111 | Lorbrena | composition of matter | 4 | 2033-03-05 |
| 9309229 | Zykadia | composition of matter | 10 | 2032-01-18 |
| 9309229 | Zykadia | composition of matter | 10 | 2032-01-18 |
| 8039479 | Zykadia | composition of matter | 10 | 2030-06-29 |
| 11299500 | Lorbrena | composition of matter | 12 | 2038-10-04 |
| 11299500 | Lorbrena | composition of matter | 12 | 2038-10-04 |
| 8039479 | Zykadia | composition of matter | 15 | 2030-06-29 |
| 7964592 | Zykadia | composition of matter | 17 | 2028-04-29 |
| 8399450 | Zykadia | composition of matter | 17 | 2027-11-20 |
Related
- Alk Fusion Gene Positive Non Small Cell Lung Cancer — full disease profile
- AI Patent Landscape Report — type "alk fusion gene positive non small cell lung cancer" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner